PHENOMENAL
OFFICIAL TITLE: MULTICENTER OPEN-LABEL, PHASE II TRIAL, TO EVALUATE THE EFFICACY AND SAFETY OF NAL-IRI FOR PROGRESSING BRAIN METASTASES IN PATIENTS WITH HER2-NEGATIVE BREAST CANCER (THE PHENOMENAL STUDY).
PRESS RELEASE
BLOG ARTICLES RELATED
SCIENTIFIC IMPACT
AACR 2018 – DOWNLOAD THE POSTER
San Antonio Breast Cancer Symposium 2024 – DOWNLOAD THE POSTER
San Antonio Breast Cancer Symposium 2024 – DOWNLOAD THE LAY LANGUAGE SUMMARY
CLINICAL TRIAL DETAILS
MULTICENTER OPEN-LABEL, PHASE II TRIAL, TO EVALUATE THE EFFICACY AND SAFETY OF NAL-IRI IN PATIENTS WITH HER2-NEGATIVE BREAST CANCER, WHO HAVE DOCUMENTED CENTRAL NERVOUS SYSTEM (CNS) PROGRESSION FOLLOWING WHOLE BRAIN RADIO THERAPY (WBRT), STEREOTACTIC RADIOSURGERY (SRS) AND/OR SURGERY, AS DETERMINED BY THE RESPONSE ASSESSMENT IN NEURO-ONCOLOGY BRAIN METASTASES (RANO-BM) CRITERIA.
PHENOMENAL AT CLINICALTRIALS.GOV
TUMOR TYPE
PHASE
HER2-NEGATIVE MBC
II
56
16
Spain
Recruiting
N
SITES
COUNTRY
STATUS
PHENOMENAL SITES
SPAIN
Instituto Oncológico Baselga - Hospital Quiron Salud Barcelona
SPAIN
Hospital Universitari Sant Joan de Reus
SPAIN
MD Anderson Cancer Center Madrid
SPAIN
Hospital Clínico San Carlos
SPAIN
Hospital Universitario Doce de Octubre
SPAIN
Hospital Universitario Miguel Servet
SPAIN
Institut Català d' Oncologia Badalona (ICO)
SPAIN
Hospital Universitario Clínico San Cecilio de Granada
SPAIN
Hospital Universitario Virgen de la Victoria
SPAIN
Hospital Universitario Ramón y Cajal
SPAIN
Instituto Valenciano de Oncología (IVO)
SPAIN
Hospital Universitario Virgen del Rocío
SPAIN
Hospital Universitari Son Espases
SPAIN
Hospital Son Llatzer
SPAIN
Ruber Juan Bravo – Hospital Quirón
SPAIN
Hospital Universitario Virgen de las Nieves